Insight Molecular Diagnostics Inc. — Director's Dealing 2016

Jan 4, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2015-12-30

Reporting Person: CHAPMAN KAREN B. (Vice President of Research)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	43799	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$1.50	2018-03-31	Common Stock (200000)		Direct
Option to Purchase Common Stock	$2.20	2025-01-08	Common Stock (100000)		Direct
Option to Purchase Common Stock	$1.34	2020-12-28	Common Stock (250000)		Indirect
Option to Purchase Common Stock	$2.20	2025-01-08	Common Stock (125000)		Indirect

Footnotes

F1: 1/48th of the number of options vested and became exercisable at the end of each full month after the date of grant on April 1, 2011.

F2: One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant on January 9, 2015 and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.

F3: 1/48th of the number of options granted to Michael West vested and became exercisable at the end of each full month after the date of grant on December 29, 2010. Dr. West and Dr. Chapman are husband and wife.

F4: One quarter of the options granted to Michael West shall vest 12 months from the date of grant on January 9, 2015 and the balance shall vest in 36 monthly installments from the first anniversary of the date of grant. Dr. West and Dr. Chapman are husband and wife.